Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Fig. 2

Adjusted incident rate ratios for death (a), MACE (b) and RAASi discontinuation (c) as a function of serum potassium in CKD patients. Black: full patient-intervals; grey: patient-intervals restricted to 30 days. Incident rate ratios were adjusted to account for confounding patient demographics, clinical histories and comorbidities, clinical measurements, and medication usage, as reported in Table 4 and Additional file 1 : Table S3. CKD: chronic kidney disease; MACE: major adverse cardiac event; RAASi: renin-angiotensin-aldosterone system inhibitor. Error bars represent 95% confidence intervals

Back to article page